Identification of patients with indolent B cell lymphoma sensitive to rituximab monotherapy. (Q53191511)

12 May 2018

title

Identification of patients with indolent B cell lymphoma sensitive to rituximab monotherapy. (English)

1 reference

12 May 2018

1 reference

2

1 reference

12 May 2018

Yves Renaudineau

9

1 reference

12 May 2018

Pierre Youinou

10

object named as

Pierre Youinou

1 reference

12 May 2018

5

Jacques-Olivier Pers

1 reference

12 May 2018

Divi Cornec

1

1 reference

12 May 2018

Solène Querellou

3

1 reference

12 May 2018

Pascal Hutin

4

1 reference

12 May 2018

Christophe Jamin

6

1 reference

12 May 2018

Boutahar Bendaoud

7

1 reference

12 May 2018

Christian Berthou

8

1 reference

12 May 2018

publication date

16 November 2011

1 reference

12 May 2018

published in

Annals of Hematology

1 reference

12 May 2018

volume

91

1 reference

12 May 2018

page(s)

715-721

1 reference

12 May 2018

issue

5

1 reference

12 May 2018

Rituximab maintenance for 2 years in patients with high tumour burden follicular lymphoma responding to rituximab plus chemotherapy (PRIMA): a phase 3, randomised controlled trial.

cites work

1 reference

https://api.crossref.org/works/10.1007%2FS00277-011-1369-Y

Monoclonal anti-CD20 antibodies: mechanisms of action and monitoring of biological effects

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00277-011-1369-Y

An overview of the current clinical use of the anti-CD20 monoclonal antibody rituximab

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00277-011-1369-Y

Rituximab-dependent cytotoxicity by natural killer cells: influence of FCGR3A polymorphism on the concentration-effect relationship.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00277-011-1369-Y

Complement-induced cell death by rituximab depends on CD20 expression level and acts complementary to antibody-dependent cellular cytotoxicity

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00277-011-1369-Y

Two immunoglobulin G fragment C receptor polymorphisms independently predict response to rituximab in patients with follicular lymphoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00277-011-1369-Y

A polymorphism in the complement component C1qA correlates with prolonged response following rituximab therapy of follicular lymphoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00277-011-1369-Y

Expression of BLyS and its receptors in B-cell non-Hodgkin lymphoma: correlation with disease activity and patient outcome.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00277-011-1369-Y

BAFF: a fundamental survival factor for B cells.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00277-011-1369-Y

Follicular lymphoma international prognostic index.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00277-011-1369-Y

Revised response criteria for malignant lymphoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00277-011-1369-Y

A new anti-idiotype antibody capable of binding rituximab on the surface of lymphoma cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00277-011-1369-Y

B-cell-activating factor inhibits CD20-mediated and B-cell receptor-mediated apoptosis in human B cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00277-011-1369-Y

Characterization of new human CD20 monoclonal antibodies with potent cytolytic activity against non-Hodgkin lymphomas

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00277-011-1369-Y

Diagnostic and prognostic impact of 18F-FDG PET/CT in follicular lymphoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00277-011-1369-Y

Pre-therapy 18F-FDG PET quantitative parameters help in predicting the response to radioimmunotherapy in non-Hodgkin lymphoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00277-011-1369-Y

Increased natural killer cell expression of CD16, augmented binding and ADCC activity to rituximab among individuals expressing the Fc{gamma}RIIIa-158 V/V and V/F polymorphism

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00277-011-1369-Y

A novel polymorphism of FcgammaRIIIa (CD16) alters receptor function and predisposes to autoimmune disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00277-011-1369-Y

The relationship of FcgammaRIIIa genotype to degree of B cell depletion by rituximab in the treatment of systemic lupus erythematosus.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00277-011-1369-Y

FCgammaRIIIA and FCgammaRIIA polymorphisms are not associated with response to rituximab and CHOP in patients with diffuse large B-cell lymphoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00277-011-1369-Y

Genetic polymorphism of the inhibitory IgG Fc receptor FcgammaRIIb is not associated with clinical outcome in patients with follicular lymphoma treated with rituximab

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00277-011-1369-Y

Complement activation determines the therapeutic activity of rituximab in vivo.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00277-011-1369-Y

The role of complement in the acquired immune response

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00277-011-1369-Y

The innate mononuclear phagocyte network depletes B lymphocytes through Fc receptor-dependent mechanisms during anti-CD20 antibody immunotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00277-011-1369-Y

Japanese multicenter phase II and pharmacokinetic study of rituximab in relapsed or refractory patients with aggressive B-cell lymphoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00277-011-1369-Y

Genetic variation in B-cell-activating factor is associated with an increased risk of developing B-cell non-Hodgkin lymphoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00277-011-1369-Y

10.1007/S00277-011-1369-Y

21 January 2018

Identifiers

DOI

1 reference

12 May 2018

PubMed ID

22083514

1 reference

12 May 2018